09637

Dr. Huading Zhang, Ph.D., is Chief Operating Officer of Alebund Pharmaceuticals (Jiangsu) Limited since January 2022. She joined Group in January 17, 2022. She serves as Director of Alebund Pharmaceuticals (Jiangsu) Limited in December 27, 2024 and serves as an executive Director since October 2025. In addition, Dr. Zhang serves as a director of Shanghai Alebund. Dr. Zhang has extensive experience in pharmaceutical research and operational management. She previously worked as a process development scientist at Cell Genesys, Inc., a biotechnology company formerly listed on the Nasdaq Global Select Market until it was acquired by BioSante Pharmaceuticals, Inc., where she was mainly responsible for the biologics process development. She then worked as a process development scientist at Amgen Inc., a biopharmaceutical company listed on the Nasdaq Global Select Market (stock code: AMGN.Nasdaq), where she was primarily responsible for overseeing the biologics process development. From November 2008 to October 2011, she served as a senior project manager at Baxter International Inc. (previously known as Vantive Healthcare (Suzhou) Co., Ltd., a medical products company listed on the New York Stock Exchange, primarily responsible for R&D project management. She served at Roche (China) Holding Ltd., a subsidiary of Roche Holding AG which is a pharmaceutical company listed on the SIX Swiss Exchange and the OTCQX International Premier market from October 2011 to November 2019, with her last position being the head of CCO. From November 2019 to January 2022, she served at Pfizer Inc., a pharmaceutical company listed on the New York Stock Exchange, with her last position being executive director and project manager of Head of Dev China department. Dr. Zhang obtained a bachelor’s degree in engineering, majoring in chemical engineering and technology from Tsinghua University in July 1998. She received her doctorate degree from the Ohio State University in December 2004.